Skip to main content
. 2021 Nov 2;13:8257–8271. doi: 10.2147/CMAR.S325246

Table 1.

Patients’ Characteristics

All Patients
Characteristics N %
Number of patients 56
Age (years)
 Median (range) 71 (51–86)
PSA before RT
 Median (range) 0.5 (0–45.56)
Gleason score
 6 2 3.6
 7 27 48.2
 8–10 27 48.2
RT dosage (Gy)
 Mean (range) 69 (63–72)
Risk groups
 Low 0 0
 Intermediate 9 16.1
 High 47 83.9
Radical prostatectomy
 No 17 30.4
 Yes 39 69.6
Resection
 R0 18 46.1
 R1 21 53.8
 R2 0 0
Biochemical relapse post-radical prostatectomy
 No 19 48.7
 Yes 20 51.3
Reason for RT administration
 Adjuvant post R1 resections 19 33.9
 Definitive treatment as single modality 17 30.4
 Salvage treatment for rising PSA after surgery 20 35.7
Anti-androgen treatment during RT
 Yes 37 66.1
 No 19 33.9
Extra-prostatic extension
 Yes 31 55.3
 No 13 23.2
 No data 12 21.4
Perineural invasion
 Yes 24 42.8
 No 15 26.7
 No available data 17 30.3
Characteristics N %
Seminal vesicles invasion
 Yes 18 32.2
 No 25 44.6
 No available data 13 23.2
Lymph node infiltration
 Yes 6 10.7
 No 36 64.3
 No available data 14 25.0
Biochemical relapse post-RT
 Yes 15 26.8
 No 41 73.2
Death
 Yes 9 16.1
 No 47 83.9

Abbreviations: Low risk, Τ1a-T2a, Gleason=6, PSA<10 ng/mL; intermediate risk, T2b-T2c, Gleason=7, PSA 10–20 ng/mL; high risk, Τ≥T3a or Gleason score=8–10 or PSA>20 ng/mL; Gy, Gray.